A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT05871918 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

832

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Breast Cancer

Interventions

DRUG: TCbHP VS ddEC-THP

Sponsor

Tianjin Medical University Cancer Institute and Hospital